ACE-083: dosing from clinical trials
Human schedule
ACE-083 is a locally acting follistatin-based ligand trap that was injected intramuscularly directly into a target muscle (tibialis anterior or biceps brachii). The figures below generalize the regimens described in published phase 2 studies.
This is a concise reference to regimens described for adults; it is not an individual prescription.
| Period / condition | Dose | Escalation |
|---|---|---|
| Starting cohort (IM, every 3 weeks) | 150 mg per muscle | Starting dose |
| Escalation (IM, every 3 weeks) | 200 mg per muscle | Increase if needed |
| Main regimen (IM, every 3 weeks) | 240 mg per muscle | Maximum in this schedule |